7.66% -0.385

Acelyrin Inc (SLRN)

Acelyrin Inc Borsa (SLRN) Ultime notizie

Acelyrin Inc (SLRN)

Acelyrin Inc Borsa (SLRN) Ultime notizie

SLRN’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle

Los Angeles Capital Management LLC Purchases New Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat

Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc - Yahoo Finance

Significant Acquisition by T. Rowe Price Investment Management i - GuruFocus.com

Acelyrin announces PoC data from Phase 1/2 trial of lonigutamab - TipRanks

ACELYRIN reports positive Phase 1/2 trial data for TED therapy - Investing.com

Acelyrin Inc (SLRN) Stock: A Year of Highs and Lows in the Market - The InvestChronicle

ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of - The Bakersfield Californian

Acelyrin, Inc. (NASDAQ:SLRN) Receives $10.83 Average Target Price from Analysts - MarketBeat

How does Acelyrin Inc (SLRN) change from a tortoise to a hare? - SETE News

Is it possible to buy Acelyrin Inc(SLRN) shares at a good price now? - US Post News

Acelyrin Inc (SLRN)’s Market Momentum: Closing Strong at 4.78, Down -0.62 - The Dwinnex

Company’s Banking Stock: Dissecting a 18.77% Quarterly Revenue Decline Amid Growth - The InvestChronicle

Financial Metrics Unveiled: Acelyrin Inc (SLRN)’s Key Ratios in the Spotlight - The Dwinnex

Stocks of Acelyrin Inc (SLRN) are poised to climb above their peers - SETE News

Was there any good news for Acelyrin Inc (SLRN) stock in the last session? - US Post News

ACELYRIN, INC. to Participate in Upcoming Investor Conferences - StockTitan

SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024 - MSN

Acelyrin (NASDAQ:SLRN) Price Target Cut to $6.00 by Analysts at Morgan Stanley - Defense World

California State Teachers Retirement System Has $49,000 Stock Position in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World

Morgan Stanley cuts Acelyrin stock target, holds equalweight on izokibep halt - Investing.com India

Acelyrin (NASDAQ:SLRN) PT Lowered to $6.00 at Morgan Stanley - MarketBeat

Morgan Stanley cuts Acelyrin stock target, holds equalweight on izokibep halt - Investing.com Canada

Closing Strong: Acelyrin Inc (SLRN) Ends at 4.13, Up 3.77 from Last Close - The Dwinnex

Morgan Stanley cuts Acelyrin stock target, holds equalweight on izokibep halt - Investing.com UK

20,703 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Acquired by Price T Rowe Associates Inc. MD - Defense World

Acelyrin (NASDAQ:SLRN) Stock Rating Lowered by HC Wainwright - Defense World

Brokerages Set Acelyrin, Inc. (NASDAQ:SLRN) Target Price at $12.00 - Defense World

Q3 2024 Earnings Forecast for Acelyrin, Inc. (NASDAQ:SLRN) Issued By HC Wainwright - MarketBeat

Q3 2024 Earnings Estimate for Acelyrin, Inc. (NASDAQ:SLRN) Issued By HC Wainwright - Defense World

Piper Sandler Lowers Acelyrin (NASDAQ:SLRN) Price Target to $20.00 - Defense World

Acelyrin, Inc. (NASDAQ:SLRN) Q2 2024 Earnings Call Transcript - Insider Monkey

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Acelyrin, Inc.(SLRN - GuruFocus.com

TD Cowen retains Buy rating on Acelyrin stock, cites strong potential - Investing.com Australia

Acelyrin (NASDAQ:SLRN) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS - Defense World

SLRN Stock Touches 52-Week Low at $3.6 Amid Market Challenges - Investing.com

Piper Sandler cuts Acelyrin stock target, maintains overweight rating - Investing.com

Acelyrin Belatedly Drops Izokibep In Its Lead Indications - Scrip

Acelyrin stock rating downgraded amid pipeline shift By Investing.com - Investing.com India

TD Cowen retains Buy rating on Acelyrin stock, cites strong potential - Investing.com India

Earnings call: Acelyrin outlines refocused pipeline and positive drug trials - Investing.com

Earnings call: Acelyrin outlines refocused pipeline and positive drug trials By Investing.com - Investing.com UK

Acelyrin stock rating downgraded amid pipeline shift By Investing.com - Investing.com Australia

Acelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

HS dropout as math favors Acelyrin’s TED course with lonigutamab - BioWorld Online

Acelyrin (NASDAQ:SLRN) PT Lowered to $20.00 at Piper Sandler - MarketBeat

Clinical Report: Acelyrin shifts priorities; Rivus moving forward in obesity - BioCentury

Piper Sandler cuts Acelyrin stock target, maintains overweight rating By Investing.com - Investing.com Canada

ACELYRIN reports positive Phase 3 trial results for izokibe By Investing.com - Investing.com Australia

Acelyrin (NASDAQ:SLRN) Announces Earnings Results - MarketBeat

Acelyrin stock rating downgraded amid pipeline shift By Investing.com - Investing.com Canada

Citi cuts Acelyrin stock target on strategic shift - Investing.com

Citi cuts Acelyrin stock target on strategic shift By Investing.com - Investing.com Canada

SLRN Stock Touches 52-Week Low at $3.6 Amid Market Challenges - Investing.com Canada

Acelyrin stock rating downgraded amid pipeline shift - Investing.com

Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep - Benzinga

TD Cowen retains Buy rating on Acelyrin stock, cites strong potential - Investing.com

TD Cowen retains Buy rating on Acelyrin stock, cites strong potential - Investing.com UK

Piper Sandler cuts Acelyrin stock target, maintains overweight rating - Investing.com India

Piper Sandler cuts Acelyrin stock target, maintains overweight rating By Investing.com - Investing.com Australia

ACELYRIN reports positive Phase 3 trial results for izokibe - Investing.com India

Citi cuts Acelyrin stock target on strategic shift - Investing.com India

Acelyrin Shares Slide on Layoffs, Portfolio Refocus - MarketWatch

Citi cuts Acelyrin stock target on strategic shift By Investing.com - Investing.com Australia

Strategic overhaul at Acelyrin after late-stage success - The Pharma Letter

SLRN Stock Touches 52-Week Low at $3.6 Amid Market Challenges - Investing.com UK

Syros shares battered after it stops leukemia trial - STAT

Acelyrin falls after H.C. Wainwright cuts to 'neutral' - XM

Acelyrin deprioritises lead therapy despite Phase III win, fires 33% of staff - Yahoo Finance

Simile a SLRN